Clinical effect of paclitaxel and carboplatin regimen chemotherapy combined with radiotherapy in treatment of stage Ⅲ cervical cancer / 肿瘤研究与临床

ABSTRACT

Objective To compare the efficacy and toxicity of paclitaxel and carboplatin regimen concurrent chemoradiotherapy and radiotherapy alone in the treatment of stage Ⅲ cervical cancer.Methods A retrospective analysis of 158 patients with stage Ⅲ cervical cancer who were admitted to Shanxi Provincial Cancer Hospital from May 2009 to October 2012 was conducted.According to different treatment methods,86 patients were in the concurrent chemoradiotherapy group and 72 patients were in the radiotherapy group.The efficacy and adverse reactions of the two groups were compared.Results The effective rate (complete remission + partial remission) in the concurrent radiotherapy group and radiotherapy group was 95.3％ (82/86) and 84.7 ％ (61/72),respectively,and the difference was statistically significant (x2 =5.15,P =0.023).The 1-,2-,3-,and 5-year survival rates of the concurrent radiotherapy group and radiotherapy group were 93.0 ％ (80/86),77.9 ％ (67/86),68.6 ％ (59/86),60.5 ％ (52/86),and 81.9 ％ (59/72),61.1％ (44/72),41.7 ％ (30/72),36.1％ (26/72),respectively,and the differences were statistically significant (x2 values were 4.55,5.29,11.56,9.30,all P ＜ 0.05).The short-term adverse reactions in the concurrent chemoradiotherapy group and radiotherapy group were mainly myelosuppression and gastrointestinal reactions,and the incidence of myelosuppression was 87.2 ％ (75/86) and 50.0 ％ (36/72),respectively,and the difference was statistically significant (x2 =25.96,P ＜ 0.01);the incidence of gastrointestinal reactions was 91.9 ％ (79/86) and 20.8 ％ (15/72),respectively,and the difference was statistically significant (x2 =82.04,P ＜ 0.01).The incidence of radiation proctitis in the concurrent radiotherapy and chemotherapy group was 17.4 ％ (15/86) and 16.7 ％ (12/72),respectively,and the difference was not statistically significant (x2 =0.017,P =0.89);the incidence of radiation cystitis was 7.0 ％ (6/86) and 5.6 ％ (4/72),respectively,and the difference was not statistically significant (x2 =0.134,P =0.71).Conclusion Paclitaxel and carboplatin regimen chemotherapy combined with radiotherapy can improve the survival rate of patients with stage Ⅲ cervical cancer,and the adverse reactions are tolerable.